KMT2A and leukemia: A combinatorial drug approach was employed, combining DOT1L inhibition with the inhibition of the MLL-Menin interaction, which resulted in significant enhancement of differentiation induction and cell killing in different models of MLL-related diseases, including primary leukemia cells (Dafflon et al., 2016).